The Role of Biological Agents in the Resection of Colorectal Liver Metastases

Clinical Oncology

Volumn 24, Issue 6, 2012, Pages 432-442

  Nordlinger, B ^a   Adam, R ^b,c,d   Arnold, D ^e   Zalcberg, J R ^f   Gruenberger, T ^g  

^a HÔPITAL AMBROISE PARÉ   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSERM   (France)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Liver metastases; Panitumumab; Resection

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLFIRI; FOLFOX; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER FUNCTION; LIVER METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS;

EID: 84863840629     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.01.002     Document Type: Article

References (80)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. Weiss L., Grundmann E., Torhorst J., et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986, 150:195-203.
3. O'Connell J.B., Maggard M.A., Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96:1420-1425.
4. Garden O.J., Rees M., Poston G.J., et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006, 55(Suppl. 3):iii1-8.
5. Nordlinger B., Van Cutsem E., Gruenberger T., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992.
6. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244:254-259.
7. De Jong M.C., Pulitano C., Ribero D., et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009, 250:440-448.
8. Livermetsurvey: international registry of liver metastases of colorectal cancer. Available at: . https://www.livermetsurvey.org/.
9. Nathan H., de Jong M.C., Pulitano C., et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg 2010, 210:755-766.
10. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240:644-657.
11. Pawlik T.M., Schulick R.D., Choti M.A. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008, 13:51-64.
12. Mayo S.C., Pawlik T.M. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009, 3:131-144.
13. Ekberg H., Tranberg K.G., Anderson R., et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986, 73:727-731.
14. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996, 77:1254-1262.
15. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
16. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
17. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26:4006-4011.
18. Weiser M., Sauerland S., Arnold D., et al. Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: a systematic review and meta-analysis of randomized trials. BMC Cancer 2010, 10:309.
19. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8:347-353.
20. Van Cutsem E., Nordlinger B., Adam R., et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006, 42:2212-2221.
21. Nordlinger B., Van Cutsem E., Rougier P., et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007, 43:2037-2045.
22. Nuzzo G., Giuliante F., Ardito F., et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007, 11:318-324.
23. Beppu T., Hayashi N., Masuda T., et al. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res 2010, 30:1015-1020.
24. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. V.2.2010. Available at: . http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
25. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
26. Saltz L.B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
27. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
28. Maughan T., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer 2009, 7(Suppl.):4. (abstract 6LBA).
29. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
30. Douillard J., Peeters M., Kohne C., et al. Safety of panitumumab (pmab) in combination with chemotherapy (ct) from five trials in 812 patients (pts) with metastatic colorectal cancer (mCRC) and wild-type (wt) KRAS tumours. J Clin Oncol 2010, 28(May 20 Suppl.):15s. (abstract 409).
31. Masi G., Salvatore L., Fornaro L., et al. Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II G.O.N.O. trial. Eur J Cancer 2009, 7(Suppl.):346. (abstract P-6081).
32. Garufi C., Torsello A., Tumolo S., et al. POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 2009, 27(Suppl.). (abstract e15020).
33. Samalin E., Desseigne F., Thézenes S., et al. Final results of a multicentre phase II trial evaluating cetuximab in combination with FOLFIRINOX as first-line treatment of metastatic colorectal cancer (mCRC) patients. Ann Oncol 2009, 20(Suppl. 7):vii20. (abstract PD-0011).
34. Okines A., Puerto O.D., Cunningham D., et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009, 101:1033-1038.
35. Wong R., Saffery C., Barbachano Y., et al. A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver only metastases from colorectal cancer unsuitable for upfront resection. Eur J Cancer 2009, 7(Suppl.):344. (abstract P-6076).
36. Emmanouilides C., Sfakiotaki G., Androulakis N., et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007, 7:91.
37. Terrebonne E., Smith D., Becouarn Y., et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: results of the ETNA cohort study. J Clin Oncol 2010, 28(Suppl.):7s. (abstract 3594).
38. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835.
39. Doi T., Boku N., Kato K., et al. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Japanese J Clin Oncol 2010, 40:913-920.
40. Ruers T., Punt C.J., van Coevorden F., et al. Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). J Clin Oncol 2010, 28(Suppl.):267s. (abstract 3526).
41. National Institute of Clinical Excellence. Colorectal cancer (first line) - cetuximab: appraisal consultation document. July 2009. Available at: . http://www.nice.org.uk/guidance/index.jsp%3Faction%3Darticle%26o%3D42937.
42. Folprecht G., Lutz M.P., Schöffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006, 17:450-456.
43. Adam R., Aloia T., Lévi F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25:4593-4602.
44. Min B.S., Kim N.K., Ahn J.B., et al. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 2007, 30:637-643.
45. Tabernero J., Van Cutsem E., Díaz-Rubio E., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25:5225-5232.
46. Arnold D., Höhler T., Dittrich C., et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008, 19:1442-1449.
47. Raoul J.L., Van Laethem J.L., Peeters M., et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009, 9:112.
48. Malka D., Paris E., Caramella C., et al. Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): a multicenter phase II study. J Clin Oncol 2010, 28(Suppl.):7s. (abstract 3558).
49. Hofheinz R., Mineur L., Griel R., et al. Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): resections and curative surgery in a phase II single arm, multicenter study (20060314). J Clin Oncol 2010, 28(Suppl.):7s. (abstract 3545).
50. Blazer D.G., Kishi Y., Maru D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344-5351.
51. Adam R., Wicherts D.A., de Haas D.J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality. J Clin Oncol 2008, 26:1635-1641.
52. Rubbia-Brandt L., Giostra E., Brezault C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007, 18:299-304.
53. Goh B.K., Chow P.K., Chuah K.L., et al. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006, 32:961-963.
54. Ribero D., Wang H., Donadon M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
55. Klinger M., Eipeldauer S., Hacker S., et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009, 35:515-520.
56. Zorzi D, Kishi Y, Maru DM, et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases. ASCO Gastrointestinal Cancers Symposium 2009;207 (abstract 295).
57. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
58. D'Angelica M., Kornprat P., Gonen M., et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007, 14:759-765.
59. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
60. Avastin - Summary of product characteristics. Avastin 25mg/ml concentrate for solution for infusion. Last updated 28 January 2010. Available at: . http://emc.medicines.org.uk/medicine/15748/SPC/Avastin%2B25mg%2Bml%2Bconcentrate%2Bfor%2Bsolution%2Bfor%2Binfusion/%23CLINICAL_PRECAUTIONS.
61. Kesmodel S.B., Ellis L.M., Lin E., et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008, 26:5254-5260.
62. Reddy S.K., Morse M.A., Hurwitz H.I., et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008, 206:96-106.
63. Adam R., Wicherts D.A., de Haas D.J., et al. Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab. J Clin Oncol 2009, 27(Suppl.):191s. (abstract 4093).
64. Kavan P., Bouganim N., Eid M., et al. Safety of bevacizumab when given perioperatively for colorectal cancer with liver metastases: McGill University pilot study. J Clin Oncol 2009, 27(Suppl.). abstract e15083.
65. Gruenberger T., Laengle F., Thaler J., et al. Pre- and postoperative chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer: a multicenter, single-arm phase II trial - Results of ASSO LM1. J Clin Oncol 2010, 28(Suppl.). abstract e14032.
66. Mahfud M., Breitenstein S., El-Badry A.M., et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 2010, 34:92-100.
67. Pessaux P., Panaro F., Casnedi S., et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 2010, 36:575-582.
68. Tamandl D., Gruenberger B., Klinger M., et al. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case control study. Ann Surg 2010, 252:124-130.
69. Erbitux - Summary of product characteristics. Erbitux 5mg/ml solution for infusion. Last updated 19 October 2009. Available at: . http://emc.medicines.org.uk/medicine/19595/SPC/Erbitux%2B5mg%2Bml%2Bsolution%2Bfor%2Binfusion/.
70. Kishi Y., Zorzi D., Contreras C.M., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010, 17:2870-2876.
71. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072.
72. Kandutsch S., Klinger M., Hacker S., et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008, 34:1231-1236.
73. Allegra C.J., Yothers G., O'Connell M.J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29:11-16.
74. De Gramont A., Van Cutsem E., Tabernero J., et al. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011, 29(Suppl. 4):139s. (abstract 362).
75. Alberts S.R., Sargent D.J., Smyrk T.C., et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG intergroup phase III trial N0147. J Clin Oncol 2010, 28(Suppl.):262s. (abstract CRA3507).
76. Chun Y.S., Vauthey J.N., Boonsirikamchai P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastas. JAMA 2009, 302:2338-2344.
77. Maru D.M., Kopetz S., Boonsirikamchai P., et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010, 34:1287-1294.
78. Sargent D.J., Patiyil S., Yothers G., et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007, 25:4569-4574.
79. Sargent D., Shi Q., Yothers G., et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011, 47:990-996.
80. Buyse M., Burzykowski T., Carroll K., et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 25:5218-5224.